Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 6/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118658 | 0.88 | KDM4E (0.66) | KDM4EPOLBRAB9AGAAALDH1A1 | |
| SCHEMBL1500236 | 0.86 | KDM4E (0.64) | KDM4EPOLBRAB9AGAAALDH1A1 | |
| SCHEMBL4098270 | 0.86 | KDM4E (0.64) | KDM4EPOLBRAB9AGAAALDH1A1 | |
| SCHEMBL70705 | 0.86 | KDM4E (0.64) | KDM4EPOLBRAB9AGAAALDH1A1 | |
| SCHEMBL3545619 | 0.86 | KDM4E (0.64) | KDM4EPOLBRAB9AGAAALDH1A1 | |
| SCHEMBL741904 | 0.86 | KDM4E (0.64) | KDM4EPOLBRAB9AGAAALDH1A1 | |
| SCHEMBL21246447 | 0.85 | RAB9A (0.52) | KDM4EPOLBRAB9AGAAALDH1A1 | |
| SCHEMBL21033471 | 0.85 | KDM4E (0.63) | KDM4EPOLBRAB9AGAAALDH1A1 | |
| Hydrochloric Acid SCHEMBL21223028 | 0.85 | KDM4E (0.63) | KDM4EPOLBRAB9AGAAALDH1A1 | |
| SCHEMBL8608432 | 0.85 | KDM4E (0.63) | KDM4EPOLBRAB9AGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119528903-A | Compounds for the treatment of spinal muscular atrophy | PTC医疗公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-108299314-B | Compounds for the treatment of spinal muscular atrophy | PTC医疗公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-118434744-A | Nitrogen-containing macrocyclic compound, and preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2024-08-02 | — | — | CN | disclosed |
| WO-2024059186-A1 | N-((ISOQUINOLIN-6-YL)METHYL)-1H-PYRAZOLE-4-CARBOXAMID DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024046512-A2 | NITROGEN-CONTAINING MACROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2024-03-07 | — | — | WO | disclosed |
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2024-02-29 | — | — | US | disclosed |
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20050171092-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-08-04 | — | — | US | disclosed |
| EP-1274701-B1 | [1,4']-BIPIPERIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| US-6903115-B2 | Bipiperidine compounds | ASTRAZENECA AB (SE) | 2005-06-07 | — | — | US | disclosed |
| EP-1493743-A1 | Substituted bipiperidine intermediates and derivatives thereof | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040014783-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-20040006080-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-6525070-B2 | For therapy of chemokine (such as CCR3) or H1 mediated disease state | ASTRAZENECA AB (SE) | 2003-02-25 | — | — | US | disclosed |
| EP-1274701-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-01-15 | — | — | EP | disclosed |
| US-20020077337-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2002-06-20 | — | — | US | disclosed |
| WO-2001077101-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | KDM4E 2384/4885POLB 1579/4885RAB9A 1350/4885 |
| US-20020077337-A1 | Chemical compounds | CCR3, CCR1, CCR4 | KDM4E 3900/4885POLB 3341/4885RAB9A 2344/4885 |
| US-20050171092-A1 | Chemical compounds | CCR3, CCR1, CCR4 | KDM4E 3589/4885POLB 3244/4885RAB9A 2189/4885 |
| US-20040006080-A1 | Chemical compounds | CCR3, CCR1, CCR4 | KDM4E 3900/4885POLB 3341/4885RAB9A 2344/4885 |
| US-20040014783-A1 | Chemical compounds | CCR3, CCR1, CCR4 | KDM4E 3900/4885POLB 3341/4885RAB9A 2344/4885 |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | SMN1; SMN2, CPT1B, GYS1 | KDM4E 1370/4885POLB 1594/4885RAB9A 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.